Influence of Periodontal Treatment on Systemic Inflammatory Mediators (Perio-CHD)
Influence of Periodontal Treatment on Systemic Inflammatory Mediators:hsC-reactive Protein, Fibrinogen and White Blood Cells in CHD Patients
Currently the research issue in establishing the role of periodontal disease (PD) in coronary heart disease (CHD) risk is to define the pathways that lead to cause-effect relationship between PD and CHD. There is no consensus on definition of a periodontal disease case or the threshold level that may give clear indication for this relationship. Periodontal therapy has been used in different studies with the hope that a change in periodontal disease status may modify the factors associated with CHD risk. Many of these studies, on role of periodontal therapy in the reduction of CHD associated risk-factors, were based on small study samples, and very few studies were randomized controlled trials. So a need for large prospective studies is warranted in literature.----------- A single-blind parallel-arm randomized controlled clinical trial was designed to observe the influence of periodontal treatment on serum inflammatory mediators of hsC-reactive protein, white blood cells and fibrinogen in CHD patients.
Hypothesis: Periodontal therapy in CHD patients, by reducing periodontal inflammation, may decrease the host systemic inflammatory burden associated with atherogenic processes.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Punjab
-
Lahore, Punjab, Pakistán, 54300
- Punjab Institute of Cardiology
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
A. General/Medical
- Any race/ethnic group
- Aged > 30 years
- Male or female
- CHD case (CHD angiographically confirmed)
- CHD diagnosed > 3 months prior to entry into study.
- No acute or chronic systemic conditions (see exclusion criteria below)
- No medications/medication history that can interfere with the study (see exclusion criteria below)
- Non-smoker (=Never smoker) or former smoker (=Does not smoke now and has not smoked at all for a minimum of the last 12 consecutive months)
- Able and willing to comply with study procedures
- Able and willing to be available for the duration of the study
- Able and willing to provide signed informed consent
B. Oral/Periodontal
- Dentate with at least 14 natural teeth, excluding third molars, that can be evaluated periodontally.
- Baseline whole mouth BOP > 20% of sites.
- Periodontitis case; periodontitis case defined as subject having ≥ 4 teeth with ≥ 1 site with PPD ≥ 4 mm & CAL ≥ 3 mm at same site
- No mechanical periodontal therapy in the last 6 months.
- No acute oral diseases (mucosal lesions), oral infections, need for immediate dental/periodontal care (e.g., NUG).
Exclusion Criteria:
A. General/Medical
- Age ≤ 30 years
- Not fulfilling criteria of defined CHD case
- Fulfilling criteria of defined CHD case, but diagnosed ≤ 3 months prior to start of study
- Current smoker
- Former smoker who does not smoke but who has smoked ≥ 1 cigarette (or equivalent, in form of water pipe, pipe, cigar) in the last 12 months.
- Females pregnant or lactating
- Systemic chronic conditions known to be associated with periodontitis or with changes in systemic inflammation: Diabetes,Rheumatoid Arthritis, Rheumatic Fever, SLE, Malignancy, Respiratory diseases, Renal diseases, Other (e.g., autoimmune diseases, fungal infections, immunological deficiencies, etc.)
- Systemic acute conditions known to affect systemic markers of inflammation: Acute bacterial infection, Acute viral infection (common cold, influenza, sinusitis), Orthopedic trauma, Surgery
- Medications known to affect systemic inflammatory biomarkers: Statins, Systemic steroids, Non-steroidal anti-inflammatory drugs, Immunosuppressants,
- Medications potentially affecting systemic inflammatory markers, if therapy started less than 3 months prior to study such as Hormone replacement therapy, Contraceptives
- Systemic antibiotic therapy in the last 3 months
- Unable or unwilling to comply with study procedures
- Unable or unwilling to be available for the duration of the study
- Unable or unwilling to provide signed informed consent
B. Oral/Periodontal
- <14 teeth that can be periodontally evaluated (excluding 3rd molars)
- BOP ≤ 20% of sites
- Not fulfilling criteria of defined periodontitis case
- Having received any periodontal therapy within last 6 months
- Topical/local antibiotic or anti-inflammatory therapy in last 6 months
- Acute oral infections
- Oral wounds, including recent (< 2 months) extractions
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Periodontal Therapy
Scaling Root planing and oral hygiene instructions
|
Scaling, root planning and oral hygiene instructions
Otros nombres:
|
|
Comparador de placebos: Delayed treatment
Scaling Root planing and oral hygiene instructions
|
Scaling, Root Planing and oral hygiene instruction
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
high-sensitivity C-Reactive Protein (hsCRP)
Periodo de tiempo: 1-3 months
|
1-3 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Fibrinogen
Periodo de tiempo: 1-3 months
|
1-3 months
|
|
White Blood Cells
Periodo de tiempo: 1-3 months
|
1-3 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Director de estudio: Ayyaz A Khan, Ph.D., Sheikh Zayed Federal Postgraduate Medical Institute
- Investigador principal: Syed Akhtar H Bokhari, MCPS, Sheikh Zayed Federal Postgraduate Medical Institute
- Silla de estudio: Mohammad Azhar, MRCP, Punjab Institute of Cardiology
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- PU-D/314/Acad
- HEC-20-685/06 (Otro número de subvención/financiamiento: Higher Education Commission, Govt of Pakistan, Islamabad)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .